Gilead to Present Liver Disease Data at 2026 Meeting
Gilead Sciences plans to present clinical and real-world evidence on primary biliary cholangitis and chronic hepatitis delta virus infection at The Liver Meeting® 2026, scheduled for November 5–9.
Gilead Sciences plans to present clinical and real-world evidence on primary biliary cholangitis and chronic hepatitis delta virus infection at The Liver Meeting® 2026, scheduled for November 5–9.